# Novel Drug Approvals at FDA

## Novel Drug Approvals for 2023

46. **Talvey**: Talvey, with the active ingredient talquetamab-tgvs, was approved on August 9, 2023, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies.

47. **Defencath**: Approved on November 15, 2023, Defencath, containing taurolidine and heparin, is used to reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter.

48. **Qalsody**: Qalsody, with the active ingredient tofersen, was approved on April 25, 2023, for the treatment of amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation.

49. **Loqtorzi**: Approved on October 27, 2023, Loqtorzi, containing toripalimab-tpzi, is used for the treatment of recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies.

50. **Daybue**: Daybue, with the active ingredient trofinetide, was approved on March 10, 2023, for the treatment of Rett syndrome.

51. **Agamree**: Approved on October 26, 2023, Agamree, containing vamorolone, is indicated for the treatment of Duchenne muscular dystrophy.

52. **Lamzede**: Lamzede, with the active ingredient velmanase alfa-tycv, was approved on February 16, 2023, for the treatment of non-central nervous system manifestations of alpha-mannosidosis.

53. **Zavzpret**: Approved on March 9, 2023, Zavzpret, containing zavegepant, is indicated for the treatment of migraine.

54. **Zilbrysq**: Zilbrysq, with the active ingredient zilucoplan, was approved on October 17, 2023, for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive.

55. **Zurzuvae**: Approved on August 4, 2023, Zurzuvae, containing zuranolone, is used for the treatment of postpartum depression.
